Author/Authors :
Valdés، نويسنده , , Rodolfo and Medina، نويسنده , , Yenisley and Ferro، نويسنده , , William and Reyes، نويسنده , , Biunayki and Geada، نويسنده , , Déborah and Montero، نويسنده , , José and Alvarez، نويسنده , , Tatiana and Leyva، نويسنده , , Alberto and Gَmez، نويسنده , , Leonardo and Padilla، نويسنده , , Sigifredo and Pacيn، نويسنده , , Leonardo and Figueroa، نويسنده , , Alejandro and Tamayo، نويسنده , , And، نويسنده ,
Abstract :
This paper evaluates the immunopurification behavior of a plantibody HBsAg specific plantibody coupled to Sepharose CL-4B at different ligand densities. Results show no significant differences in the adsorption and elution capacities, and rHBsAg recovery of immunosorbents at 3.43, 4.45, and 5.31 mg/mL of ligand densities compared to its mouse-derived mAb counterpart consistently used in the rHBsAg purification process. Therefore, plantibody ligand densities higher than 3.43 mg/mL do not improve the immunopurification behavior of this immunosorbent, but increase the antibody consumption and the Hepatitis B vaccine cost. Immunosorbent of 2.23 mg/mL of ligand density demonstrated a poor performance. The IgG leached detectable level never exceeded the approved limit (3 ng IgG/μg rHBsAg). Values close to this limit were only observed at the ligand density of 5.31 and 2.27 mg/mL. In the case of the ligand density of 2.23 mg/mL the IgG leached value was high (2.90 ng IgG/μg rHBsAg) due to a low level of eluted antigen. In conclusion, it supports feasibility of using this plantibody at 3.43 mg/mL of ligand density for large-scale immunopurification of rHBsAg for human use, avoiding the biosafety and ethical concerns of the massive use of animals for this purpose.
Keywords :
Plant-derived antibody , Plantibody , monoclonal antibody , Immunoaffinity , Immunopurification , Hepatitis B virus surface antigen